Home › Funds › PERCEPTIVE ADVISORS LLC › DYN
PERCEPTIVE ADVISORS LLC position in DYN
DYNE THERAPEUTICS INC · Health Care
PERCEPTIVE ADVISORS LLC reported holding 2,689,235 shares of DYN (DYNE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$59.7M, representing 0.95% of its reported portfolio and ranking #26 among its reported holdings. PERCEPTIVE ADVISORS LLC has disclosed DYN holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How PERCEPTIVE ADVISORS LLC's DYN position evolved
PERCEPTIVE ADVISORS LLC first disclosed a stake in DYN in Q3 2024 at 718,144 shares (US$25.8M). The position peaked in Q1 2026 at 4,668,839 shares, worth US$84.6M. Across 8 filings, PERCEPTIVE ADVISORS LLC increased the stake 3 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,689,235 shares valued at US$59.7M — a reduction of -1,979,604 shares quarter over quarter.. Notable position changes include a 326% increase in Q1 2025 (shares fell 9% over the following quarter), a 76% trim in Q3 2025 (shares rose 55% over the following quarter), a 544% increase in Q4 2025 (shares fell 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 718.14K | $25.80M | New |
| Q4 2024 | 543.28K | $12.80M | Reduce |
| Q1 2025 | 2.31M | $24.20M | Add |
| Q2 2025 | 2.25M | $21.40M | Reduce |
| Q3 2025 | 540.44K | $6.84M | Reduce |
| Q4 2025 | 3.48M | $68.05M | Add |
| Q1 2026 | 4.67M | $84.65M | Add |
| Q2 2026 | 2.69M | $59.73M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DYN and 13F data
DYN (DYNE THERAPEUTICS INC) is a Health Care company. 41 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DYN
- Atlas Venture Life Science Advisors, LLC 6.80M sh · $151.03M · Q2 2026
- TCG Crossover Management, LLC 4.62M sh · $102.50M · Q2 2026
- FCPM III SERVICES B.V. 3.85M sh · $85.47M · Q2 2026
- Vestal Point Capital, LP 3.38M sh · $74.96M · Q2 2026
- ORBIMED ADVISORS LLC 3.24M sh · $71.86M · Q2 2026
- Frazier Life Sciences Management, L.P. 3.15M sh · $70.03M · Q2 2026
- ARMISTICE CAPITAL, LLC 3.09M sh · $68.57M · Q2 2026
- Logos Global Management LP 2.55M sh · $56.64M · Q2 2026
- Venrock Adviser, LLC 2.17M sh · $48.28M · Q2 2026
- Siren, L.L.C. 2.13M sh · $47.29M · Q2 2026
- MPM BioImpact LLC 1.92M sh · $42.69M · Q2 2026
- SAMLYN CAPITAL, LLC 1.75M sh · $38.97M · Q2 2026
More on PERCEPTIVE ADVISORS LLC
FAQ
How long has PERCEPTIVE ADVISORS LLC held DYN?
PERCEPTIVE ADVISORS LLC has disclosed DYN holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
What is PERCEPTIVE ADVISORS LLC's current position in DYN?
As of Q2 2026, PERCEPTIVE ADVISORS LLC holds 2.69M shares of DYN (DYNE THERAPEUTICS INC), valued at $59.73M, representing 0.95% of its reported portfolio and ranking #26.
Has PERCEPTIVE ADVISORS LLC been buying or selling DYN?
In the latest 13F filing (Q2 2026), PERCEPTIVE ADVISORS LLC reduced its position in DYN. The position peaked in Q1 2026 at 4.67M shares.
Which other funds hold DYN?
Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.